Advantages of updated WHO mutation catalog combined with existing whole-genome sequencing-based approaches for Mycobacterium tuberculosis resistance prediction.

For second-line drugs, the ensemble model (91.8% [89.6–94.0%]) outperformed MD-CNN (90.3% [87.9–92.7%]), although this result was only marginally significant (Wilcoxon signed-rank test with Benjamini–Hochberg FDR p = 0.09).

also in 5,076 other papers